{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T18:18:11Z","timestamp":1788286691079,"version":"build-2803163510"},"reference-count":44,"publisher":"MDPI AG","issue":"13","license":[{"start":{"date-parts":[[2023,7,2]],"date-time":"2023-07-02T00:00:00Z","timestamp":1688256000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"National Research Fund of Korea","award":["NRF-2021R1I1A20474750"],"award-info":[{"award-number":["NRF-2021R1I1A20474750"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Although recent studies have shown favorable results after local treatment for oligometastases, the clinical decision of applying local treatment for oligometastatic hepatocellular carcinoma (HCC) remains controversial. This meta-analysis aimed to investigate the benefits of local treatment for HCC oligometastases. Pubmed, Embase, Medline, and the Cochrane library were searched for studies until 1 May 2022. Clinical studies involving at least five cases of HCC oligometsatases treated with local modalities were included. The primary endpoint was overall survival (OS). The benefit of local treatment was assessed as the pooled odds ratio (OR) among comparative series, and the pooled OS percentile was calculated from all studies including patients treated with local treatment. Complications of grade \u2265 3 were assessed subjectively. A total of 10 studies involving 527 patients were included. Radiotherapy and radiofrequency ablation (RFA) were mainly performed (six and five studies) as local modalities treating oligometastases. Pooled OR of comparative series favored the use of local treatment (4.664, 95% confidence interval [CI]: 2.595\u20138.380, p &lt; 0.001, I2: ~0.0%). Including all cohorts with patients who underwent local treatment, pooled rates of 1-year OS were 71.8% (95% CI: 59.0\u201381.9; I2 = 81.5%), and pooled 2-year OS were 43.3% (95% CI: 29.1\u201359.6; I2 = 85.4%). Except for temporal or pre-existing toxicities, grade \u2264 3 complications were reported less than 10% in most studies, although common toxicities include pneumothorax and hematologic deficiency after RFA and radiotherapy, respectively. Grade 5 toxicity has not yet been reported. This systematic review supports the application of local treatment for treating HCC oligometastases.<\/jats:p>","DOI":"10.3390\/cancers15133467","type":"journal-article","created":{"date-parts":[[2023,7,3]],"date-time":"2023-07-03T00:49:27Z","timestamp":1688345367000},"page":"3467","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Local Treatment of Hepatocellular Carcinoma with Oligometastases: A Systematic Review and Meta-Analysis"],"prefix":"10.3390","volume":"15","author":[{"given":"Sooyeon","family":"Kim","sequence":"first","affiliation":[{"name":"College of Medicine, Korea University, Seoul 02841, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jungsue","family":"Lee","sequence":"additional","affiliation":[{"name":"College of Medicine, Korea University, Seoul 02841, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7431-4588","authenticated-orcid":false,"given":"Chai Hong","family":"Rim","sequence":"additional","affiliation":[{"name":"College of Medicine, Korea University, Seoul 02841, Republic of Korea"},{"name":"Department of Radiation Oncology, Korea University Ansan Hospital, Ansan 15355, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,7,2]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/S0022-5223(97)70397-0","article-title":"Long-term results of lung metastasectomy: Prognostic analyses based on 5206 cases","volume":"113","author":"Pastorino","year":"1997","journal-title":"J. Thorac. Cardiovasc. Surg."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/S1470-2045(20)30537-4","article-title":"Stereotactic ablative body radiotherapy in patients with oligometastatic cancers: A prospective, registry-based, single-arm, observational, evaluation study","volume":"22","author":"Chalkidou","year":"2021","journal-title":"Lancet Oncol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1200\/JCO.1995.13.1.8","article-title":"Oligometastases","volume":"13","author":"Hellman","year":"1995","journal-title":"J. Clin. Oncol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1038\/nrclinonc.2011.44","article-title":"Oligometastases revisited","volume":"8","author":"Weichselbaum","year":"2011","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"4250","DOI":"10.1200\/JCO.22.01482","article-title":"Oligometastases: Emerging Evidence","volume":"40","author":"Liu","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.1200\/JCO.19.00201","article-title":"Local consolidative therapy vs. maintenance therapy or observation for patients with oligometastatic non\u2013small-cell lung cancer: Long-term results of a multi-institutional, phase II, randomized study","volume":"37","author":"Gomez","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"e173501","DOI":"10.1001\/jamaoncol.2017.3501","article-title":"Consolidative radiotherapy for limited metastatic non\u2013small-cell lung cancer: A phase 2 randomized clinical trial","volume":"4","author":"Iyengar","year":"2018","journal-title":"JAMA Oncol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1200\/JCO.2017.75.4853","article-title":"Surveillance or metastasis-directed therapy for oligometastatic prostate cancer recurrence: A prospective, randomized, multicenter phase II trial","volume":"36","author":"Ost","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"2353","DOI":"10.1016\/S0140-6736(18)32486-3","article-title":"Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): A randomised controlled phase 3 trial","volume":"392","author":"Parker","year":"2018","journal-title":"Lancet"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1038\/s41698-020-00141-4","article-title":"Benefits of local consolidative treatment in oligometastases of solid cancers: A stepwise-hierarchical pooled analysis and systematic review","volume":"5","author":"Rim","year":"2021","journal-title":"NPJ Precis. Oncol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1002\/ijc.31937","article-title":"Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods","volume":"144","author":"Ferlay","year":"2019","journal-title":"Int. J. Cancer"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"393","DOI":"10.3892\/mco.2014.259","article-title":"Clinical characteristics and prognostic factors for advanced hepatocellular carcinoma with extrahepatic metastasis","volume":"2","author":"Aino","year":"2014","journal-title":"Mol. Clin. Oncol."},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Facciorusso, A., Abd El Aziz, M.A., Tartaglia, N., Ramai, D., Mohan, B.P., Cotsoglou, C., Pusceddu, S., Giacomelli, L., Ambrosi, A., and Sacco, R. (2020). Microwave Ablation Versus Radiofrequency Ablation for Treatment of Hepatocellular Carcinoma: A Meta-Analysis of Randomized Controlled Trials. Cancers, 12.","DOI":"10.3390\/cancers12123796"},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Granito, A., Facciorusso, A., Sacco, R., Bartalena, L., Mosconi, C., Cea, U.V., Cappelli, A., Antonino, M., Modestino, F., and Brandi, N. (2021). TRANS-TACE: Prognostic Role of the Transient Hypertransaminasemia after Conventional Chemoembolization for Hepatocellular Carcinoma. J. Pers. Med., 11.","DOI":"10.3390\/jpm11101041"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.radonc.2018.12.005","article-title":"Clinical feasibility and efficacy of stereotactic body radiotherapy for hepatocellular carcinoma: A systematic review and meta-analysis of observational studies","volume":"131","author":"Rim","year":"2019","journal-title":"Radiother Oncol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1148\/radiol.2016151807","article-title":"Percutaneous CT-guided radiofrequency ablation for lymph node oligometastases from hepatocellular carcinoma: A propensity score\u2013matching analysis","volume":"282","author":"Pan","year":"2017","journal-title":"Radiology"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"35","DOI":"10.2147\/JHC.S290197","article-title":"Efficacy of local therapy for oligometastatic hepatocellular carcinoma: A propensity score matched analysis","volume":"8","author":"Kim","year":"2021","journal-title":"J. Hepatocell. Carcinoma"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S1470-2045(08)70285-7","article-title":"Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: A phase III randomised, double-blind, placebo-controlled trial","volume":"10","author":"Cheng","year":"2009","journal-title":"Lancet Oncol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"e210037","DOI":"10.1001\/jamanetworkopen.2021.0037","article-title":"Cost-effectiveness of Atezolizumab Plus Bevacizumab vs Sorafenib as First-Line Treatment of Unresectable Hepatocellular Carcinoma","volume":"4","author":"Su","year":"2021","journal-title":"JAMA Netw. Open"},{"key":"ref_20","first-page":"1","article-title":"The Newcastle-Ottawa scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses","volume":"2","author":"Peterson","year":"2011","journal-title":"Ott. Ott. Hosp. Res. Inst."},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Higgins, J.P., Thomas, J., Chandler, J., Cumpston, M., Li, T., Page, M.J., and Welch, V.A. (2019). Cochrane Handbook for Systematic Reviews of Interventions, John Wiley & Sons.","DOI":"10.1002\/9781119536604"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1745","DOI":"10.7150\/jca.24568","article-title":"Sorafenib monotherapy versus sorafenib combined with regional therapies for hepatocellular carcinoma patients with pulmonary oligometastases: A propensity score-matched analysis","volume":"9","author":"Chen","year":"2018","journal-title":"J. Cancer"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"101","DOI":"10.2307\/3001666","article-title":"The Combination of Estimates from Different Experiments","volume":"10","author":"Cochran","year":"1954","journal-title":"Biometrics"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1002\/sim.1186","article-title":"Quantifying heterogeneity in a meta-analysis","volume":"21","author":"Higgins","year":"2002","journal-title":"Stat. Med."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1111\/j.0006-341X.2000.00455.x","article-title":"Trim and fill: A simple funnel-plot-based method of testing and adjusting for publication bias in meta-analysis","volume":"56","author":"Duval","year":"2000","journal-title":"Biometrics"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1093\/jjco\/hyac028","article-title":"Stereotactic ablative radiotherapy for pulmonary oligometastases from primary hepatocellular carcinoma: A multicenter and retrospective analysis (KROG 17-08)","volume":"52","author":"Jo","year":"2022","journal-title":"Jpn. J. Clin. Oncol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"2693","DOI":"10.1007\/s00432-021-03553-2","article-title":"Improved oncologic outcomes by ablative radiotherapy in patients with bone metastasis from hepatocellular carcinoma","volume":"147","author":"Kim","year":"2021","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1080\/02656736.2019.1663279","article-title":"Survival benefits of computed tomography-guided thermal ablation for adrenal metastases from hepatocellular carcinoma","volume":"36","author":"Lyu","year":"2019","journal-title":"Int. J. Hyperth."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1093\/jrr\/rraa067","article-title":"Stereotactic body radiotherapy delivered with IMRT for oligometastatic regional lymph node metastases in hepatocellular carcinoma: A single-institutional study","volume":"61","author":"Matoba","year":"2020","journal-title":"J. Radiat. Res."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1080\/02656736.2017.1318332","article-title":"Percutaneous CT-guided radiofrequency ablation for patients with extrahepatic oligometastases of hepatocellular carcinoma: Long-term results","volume":"34","author":"Mu","year":"2018","journal-title":"Int. J. Hyperth."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1016\/j.jvir.2016.05.017","article-title":"Long-term survival after radiofrequency ablation of lung oligometastases from five types of primary lesions: A retrospective evaluation","volume":"27","author":"Omae","year":"2016","journal-title":"J. Vasc. Interv. Radiol."},{"key":"ref_32","first-page":"S540","article-title":"Stereotactic Ablative radiotherapy for pulmonary oligometastasis from hepatocellular carcinoma","volume":"8","author":"Song","year":"2013","journal-title":"J. Thorac. Oncol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1002\/hep.27443","article-title":"Prognosis of untreated hepatocellular carcinoma","volume":"61","author":"Giannini","year":"2015","journal-title":"Hepatology"},{"key":"ref_34","first-page":"3","article-title":"Untreated hepatocellular carcinoma in Egypt: Outcome and prognostic factors","volume":"2","author":"Zeeneldin","year":"2015","journal-title":"J. Hepatocell. Carcinoma"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1056\/NEJMoa0708857","article-title":"Sorafenib in advanced hepatocellular carcinoma","volume":"359","author":"Llovet","year":"2008","journal-title":"N. Engl. J. Med."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1056\/NEJMoa1915745","article-title":"Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma","volume":"382","author":"Finn","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_37","first-page":"953","article-title":"Role of Local Treatment for Oligometastasis: A Comparability-Based Meta-Analysis","volume":"54","author":"Rim","year":"2022","journal-title":"Cancer Res. Treat. Off. J. Korean Cancer Assoc."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"353","DOI":"10.21037\/hbsn.2018.08.01","article-title":"Multidisciplinary management of recurrent and metastatic hepatocellular carcinoma after resection: An international expert consensus","volume":"7","author":"Wen","year":"2018","journal-title":"Hepatobiliary Surg. Nutr."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"100594","DOI":"10.1016\/j.jhepr.2022.100594","article-title":"Comparison of radiofrequency ablation and ablative external radiotherapy for the treatment of intrahepatic malignancies: A hybrid meta-analysis","volume":"5","author":"Rim","year":"2022","journal-title":"JHEP Rep."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1159\/000500461","article-title":"Irradiation-Related Lymphopenia for Bone Metastasis from Hepatocellular Carcinoma","volume":"8","author":"Park","year":"2019","journal-title":"Liver Cancer"},{"key":"ref_41","doi-asserted-by":"crossref","unstructured":"Rim, C.H., Park, S., Shin, I.S., and Yoon, W.S. (2021). Is the Concurrent Use of Sorafenib and External Radiotherapy Feasible for Advanced Hepatocellular Carcinoma? A Meta-Analysis. Cancers, 13.","DOI":"10.3390\/cancers13122912"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"2008","DOI":"10.1001\/jama.283.15.2008","article-title":"Meta-analysis of observational studies in epidemiology: A proposal for reporting","volume":"283","author":"Stroup","year":"2000","journal-title":"JAMA"},{"key":"ref_43","doi-asserted-by":"crossref","unstructured":"Shin, I.-S., and Rim, C.H. (2021). Updating Perspectives on Meta-Analyses in the Field of Radiation Oncology. Medicina, 57.","DOI":"10.3390\/medicina57020117"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1093\/aje\/kwm189","article-title":"Should meta-analyses of interventions include observational studies in addition to randomized controlled trials? A critical examination of underlying principles","volume":"166","author":"Shrier","year":"2007","journal-title":"Am. J. Epidemiol."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/15\/13\/3467\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T20:04:49Z","timestamp":1760126689000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/15\/13\/3467"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,2]]},"references-count":44,"journal-issue":{"issue":"13","published-online":{"date-parts":[[2023,7]]}},"alternative-id":["cancers15133467"],"URL":"https:\/\/doi.org\/10.3390\/cancers15133467","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7,2]]}}}